What does a PROSE Device cost?

Transparent pricing for custom prosthetic lenses requires understanding the bundled clinical and manufacturing model.

PROSE treatment is bundled: patients pay for clinical fitting visits, device fabrication, and ongoing support—not a separate hardware purchase. Historical estimates from PROSE forums suggest costs ranging from $7,000 to $20,000 , though actual fees vary significantly by center and insurance coverage. In 2009, the average cost per fitted patient was $12,300 (approximately half for clinical services and half to produce the prosthesis) for bilateral fitting, decreasing to approximately $8,000 for a single prosthesis . These figures are now 15+ years old; current list pricing is rarely published because nearly 80% of patients treated at Boston Foundation for Sight in 2010 received partial or full insurance coverage, with staff working closely with insurers to obtain reimbursement . Out-of-pocket costs depend on insurance carrier decisions, clinic location, and whether financial assistance programs apply.

What the typical range is

No aggregate pricing database currently exists for PROSE devices. Published cost data is sparse because the device is manufactured by a single entity—Boston Foundation for Sight / BostonSight—and distributed only through credentialed clinical partnerships at major academic medical centers. There are fewer than 20 PROSE treatment centers worldwide , and each center manages its own fee schedule independently. Without current list prices from BostonSight, procurement officers should expect:

• Bilateral device cost (historical baseline): $12,300 (2009 dollars; adjust 3–4% annually for inflation)
• Monocular device cost (historical baseline): $8,000 (2009 dollars)
• Most recent interval data: $7,600 cited circa 2010 as "fixed fee for the entire fitting process"

These figures bundled clinical evaluation, fitting visits, device manufacturing, and initial training. Today's actual costs are not publicly verifiable, and MedSource does not yet have aggregated quotes from healthcare provider organizations.

What pushes price up — features, certifications, support tier

Device customization complexity is the primary cost driver. PROSE devices allow for specifications and unique customization in up to 8 independent meridians of the lens , compared to standard scleral lenses offering only 2–4 meridians. Custom eight-meridian fitting requires CAD-CAM manufacturing and iterative clinical refinement, increasing fabrication labor and material waste.

Bilateral vs. monocular fitting roughly doubles the device cost. Most patients with severe dry eye or ocular graft-versus-host disease require two devices (one per eye).

Clinical fellowship training requirement: PROSE ophthalmologists and optometrists complete an intensive BostonSight PROSE Clinical Fellowship before they can provide treatment . This gatekeeping restricts supply and allows premium pricing at authorized centers.

Fitting duration and clinical intensity: Treatment can last anywhere between 5–10 days until the PROSE clinician and patient are satisfied with the outcome . Multiple visits, refraction, topography, and device iterations are bundled into the fee. More complex corneal pathology (keratoconus, Stevens-Johnson syndrome, ocular GVHD) may require longer fitting windows, increasing labor allocation.

Regulatory pathway: The prosthetic devices used in PROSE treatment were Food and Drug Administration approved in 1994 for daily wear in the management of distorted cornea and certain disorders of the ocular surface . FDA-cleared (not PMA) status reduces regulatory compliance burden but does not lower the manufacturer's proprietary design premium.

What pushes price down — refurbished, older generation, lease, GPO contracts

Refurbished or patient-returned devices: Because PROSE devices are custom-molded to individual eye geometry, no secondary market for refurbished devices exists. Each device is destroyed or archived at end-of-life; reuse is not clinically or legally feasible.

Leasing or lease-to-own models: Clinics do not lease PROSE devices. The treatment model is fee-for-service (clinical + device bundled), not recurring hardware rental.

GPO or volume contracts: There is no known Group Purchasing Organization contract for PROSE devices. The single-manufacturer model and limited clinical network (< 20 centers) preclude competitive GPO bidding. Each hospital or clinic negotiates independently with BostonSight.

Older generations or clearance: Because BostonSight manufactures devices on-site at each clinic, there is no inventory clearance or generational obsolescence. All devices are manufactured to order post-fitting.

Self-pay or out-of-pocket negotiation: Financial assistance is available for those who qualify , and BostonSight's patient advocacy explicitly addresses affordability. Centers may offer sliding-scale fees or deferred payment, but published discounts are not standard.

Hidden costs — install, training, calibration, consumables, service contracts

Preservative-free saline (ongoing): The devices are filled with preservative-free saline each day at the time of application, and are removed at bedtime . Annual saline consumption for bilateral wear (~365 fills × 2 eyes) costs approximately $300–$600, depending on brand and source (Bausch SVP or LacriPure are common). This is patient responsibility.

Cleaning solutions and storage cases: BostonSight recommends specific enzymatic cleaners and rigid lens storage cases (approximately $50–$150 per year per patient). Some patients use hydrogen peroxide systems (Bausch Clear Care or equivalent) costing ~$100 annually.

Device damage or loss: PROSE devices are durable but breakable. Repair or replacement of a damaged device incurs a separate fabrication fee (unpublished, likely $2,000–$4,000 per device) and requires return to a credentialed clinic for refit.

Training and instruction: Worn during waking hours, patients are trained in their daily application, removal and cleaning . Fitting clinics include instruction in the bundled fee; additional training sessions are rare unless fitting complications arise.

Follow-up clinical visits: Treatment involves 5–10 day-long visits, periodic follow-up visits as required during the first 6 months, and annual evaluation of PROSE fit annually . Post-device costs for annual exams or refitting are typically billed separately (estimate: $300–$800 per visit, depending on center and whether insurance covers it as "prosthetic device maintenance" vs. "routine refraction").

Educator or patient-support coordination: Large academic centers may include lodging or meal subsidies for out-of-state patients as part of patient assistance; standalone practices do not.

How to negotiate — concrete tactics

1. Obtain formal quotes from multiple authorized PROSE clinics (if possible). Verify each clinic's fee structure in writing: itemize clinical evaluation, fitting visits, device manufacturing, training, and first-year follow-up. Many clinics bundle these; ask for line-item breakdown to identify negotiating leverage.

2. Verify insurance coverage before committing. When the PROSE device is used as a treatment for certain types of dry eye the device must be coded as a scleral shell with HCPCS code V2627 (scleral cover shell) . Ensure your payer recognizes this code and has a fee schedule. Medicare's PDAC can clarify coding and coverage; contact them at (877) 735-1326.

3. Inquire about financial assistance programs at clinics affiliated with BostonSight. Staff explicitly manage insurance reimbursement and patient affordability; ask about income-based discounts, payment plans, or charitable care.

4. Bundle bilateral fitting: If a patient requires binocular devices, some centers offer modest discounts (5–10%) on the second device compared to sequential monocular purchases.

5. Clarify what happens after the fitting period. Confirm whether annual follow-up visits, replacement saline, or device adjustments are included in the original fee or billed separately.

6. Ask about clinical trial or research eligibility. Some academic centers conduct PROSE outcomes studies and may reduce or waive fees for eligible participants.

When the price feels off — red flags

• No transparency on device vs. clinical labor allocation: Legitimate clinics will break down the ~50/50 split between device cost and clinical services cost. Refusal to itemize suggests overcharging.
• Clinics claiming "wholesale" discounts below $7,000 per device: This is below historical monocular baselines adjusted for inflation (2009 $8,000 → 2026 ~$10,500). Be skeptical of unverifiable claims.
• No mention of iterative fitting or multiple visits: If a clinic guarantees a fit in one visit, they are either exceptionally experienced or oversimplifying a complex custom-manufacturing process. Most require 5–10 days.
• No insurance verification protocol: Legitimate clinics proactively verify coverage and pursue reimbursement. If a clinic is silent on insurance, you may pay out-of-pocket regardless of coverage.
• Refusal to itemize follow-up care costs: Annual exams, device maintenance, and saline refills should have a clear cost structure. Vague "additional charges as needed" suggests variable pricing.
• Claims that PROSE is a "onetime" purchase requiring no ongoing visits: Periodic follow-up visits are required during the first 6 months, and annual evaluation of PROSE fit is recommended . Any clinic promising no follow-up is misrepresenting the treatment model.

Sources

• MillennialEYE, "The PROSE Device for OSD and Corneal Ectasia" (2016). Historical cost-effectiveness analysis citing 2009 pricing.
• BostonSight, "PROSE Treatment: Info for Practitioners" (August 2024). Device design specifications and fitting protocol.
• EyeWiki, "BostonSight PROSE and Scleral Contact Lenses" (January 2026). Regulatory and design comparison.
• Noridian Medicare, "PROSE Device – Correct Coding" (archived DME coding guidance). HCPCS V2627 and coverage criteria.
• Dry Eye Zone Forums (circa 2010). Patient-reported pricing and financial assistance pathways.
• ScienceDirect / PubMed, "Prosthetic Replacement of the Ocular Surface Ecosystem Treatment of Ocular Surface Disease After Skull Base Tumor Resection" (2017). Clinical outcomes and FDA approval timeline.
• UCSF Health, Baylor Medicine, Weill Cornell Medicine, Michigan Medicine, "PROSE Clinic" pages (2024–2025). Current clinical center information and patient care protocols.

This article reflects publicly verifiable data as of May 2026 and will be updated as MedSource accumulates healthcare provider quote data.